High dose ifosfamide and adriamycin in the treatment of soft tissue sarcomas

Background. To evaluate the efficacy and toxicity of dose-dense high dose ifosfamide and adriamycin in the treatment of locally advanced and metastatic soft tissue sarcomas. Materials and methods. 26 patients where included in the interim analysis by the end of 2009. Dose dense high dose (DDHD) AI ifosfamide 2000 mg/m² IV 1-5 days with adriamycin 60 mg/m² IV day 1 with GM-CSF support 6-14 once in 2 weeks was used in 23 STS patients. Male 60%, female 40% with the median age of 42 years old (22-63 years old). From 26 patients at the beginning of DDHD AI chemotherapy 10 patients were locally advanced, and 16 - with distant metastases. Tumor assessment was made according to RECIST criteria after every 2 cycles. Histology - synovial 11 pts, MFH - 3 pts, lipo - 6 pts, leiomyo - 1 and 2 NOS sarcomas. Results. Objective response has achieved in 43,5% (CR - 13,1%, PR - 30,4%), stable disease - 39,1%, disease progression in 17,4%. Toxicity profile was manageable and mild: leucopenia 56% with Gr 3-4 23%, neutropenia - 47% (Gr 3-4 - 9%), anemia - 52% with no Gr 3-4, thrombocytopenia 17% (Gr 3-4 - 9%). Conclusion. This chemotherapy regimen seems to be very active in the treatment of STS patients with mild and manageable toxicity profile and needs further evaluation of the impact on overall survival and time to progression. This trial is still ongoing.

soft tissue sarcoma, chemotherapy, dose-dense ifosfamide, doxorubicin